The frequencies of aberrant p53 expression in our study, affecting 19% of HR + HER2 − , 62% of HER2 + cases and 92% of TNBC were consistent with the documented mutation rates for the different subtypes of BC [27]. This evidence concerns the gene ERBB2 and breast cancer.